Abbott Total Assets from 2010 to 2024

ABT Stock

USD 118.13 0.37 0.31%

Abbott Laboratories Total Assets yearly trend continues to be comparatively stable with very little volatility. Total Assets will likely drop to about 36.9 B in 2024. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

1985-12-31

Previous Quarter

73 B

Current Value

74.4 B

Quarterly Volatility

24.6 B

Black Monday

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Abbott Laboratories financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Abbott Laboratories' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.4 B, Interest Expense of 605.1 M or Selling General Administrative of 6.2 B, as well as many indicators such as Price To Sales Ratio of 5.0, Dividend Yield of 0.0177 or PTB Ratio of 2.62. Abbott financial statements analysis is a perfect complement when working with Abbott Laboratories Valuation or Volatility modules.

Check out the analysis of Abbott Laboratories Correlation against competitors.

For more information on how to buy Abbott Stock please use our How to Invest in Abbott Laboratories guide.

Latest Abbott Laboratories' Total Assets Growth Pattern

Below is the plot of the Total Assets of Abbott Laboratories over the last few years. Total assets refers to the total amount of Abbott Laboratories assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Abbott Laboratories books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Abbott Laboratories' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Abbott Laboratories' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 73.21 B

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Abbott Total Assets Regression Statistics

	Arithmetic Mean	56,845,462,665
	Geometric Mean	48,710,968,801
	Coefficient Of Variation	35.90
	Mean Deviation	16,347,823,068
	Median	67,173,000,000
	Standard Deviation	20,407,500,419
	Sample Variance	416466073.4T
	Range	72.8B
	R-Value	0.50
	Mean Square Error	336704677.6T
	R-Squared	0.25
	Significance	0.06
	Slope	2,278,285,867
	Total Sum of Squares	5830525027.2T

Abbott Total Assets History

	2024	36.9 B
	2023	73.2 B
	2022	74.4 B
	2021	75.2 B
	2020	72.5 B
	2019	67.9 B
	2018	67.2 B

Other Fundumenentals of Abbott Laboratories

Intangibles To Total Assets

Abbott Laboratories Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Accounts Payable	Current Deferred Revenue	Short Term Investments	Common Stock	Intangible Assets	Long Term Debt	Treasury Stock	Property Plant Equipment	Good Will	Net Tangible Assets	Long Term Debt Total	Long Term Investments	Accumulated Depreciation	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.75	0.77	0.61	0.86	0.97	0.74	-0.15	0.63	-0.3	-0.06	0.05	0.74	0.78	-0.62	0.8	0.88	-0.34	0.58	-0.23	-0.35	0.26	-0.54	-0.18	-0.33	0.04
Total Stockholder Equity	0.75		0.55	0.93	0.66	0.65	0.49	-0.03	0.89	-0.36	-0.06	-0.1	0.58	0.53	-0.74	0.83	0.81	0.01	0.38	-0.24	-0.47	0.35	-0.7	-0.65	-0.39	0.65
Net Debt	0.77	0.55		0.29	0.6	0.81	0.26	-0.42	0.49	-0.14	-0.2	0.01	0.98	0.8	-0.39	0.58	0.86	-0.73	0.71	-0.27	-0.22	-0.01	-0.73	-0.33	-0.58	-0.03
Retained Earnings	0.61	0.93	0.29		0.52	0.5	0.5	0.12	0.8	-0.42	-0.09	-0.16	0.31	0.39	-0.81	0.7	0.59	0.27	0.24	0.02	-0.36	0.45	-0.51	-0.59	-0.24	0.7
Net Receivables	0.86	0.66	0.6	0.52		0.84	0.77	0.08	0.54	-0.05	0.21	0.38	0.52	0.54	-0.27	0.82	0.73	-0.2	0.36	-0.42	-0.6	0.09	-0.31	-0.13	-0.18	0.09
Total Liab	0.97	0.65	0.81	0.5	0.84		0.75	-0.21	0.54	-0.24	-0.07	0.13	0.76	0.88	-0.52	0.72	0.82	-0.45	0.7	-0.19	-0.36	0.21	-0.48	-0.13	-0.29	-0.02
Total Current Assets	0.74	0.49	0.26	0.5	0.77	0.75		0.2	0.28	-0.31	0.34	0.18	0.18	0.56	-0.36	0.52	0.38	0.06	0.34	-0.14	-0.32	0.27	0.06	0.17	0.18	-0.03
Short Term Debt	-0.15	-0.03	-0.42	0.12	0.08	-0.21	0.2		-0.3	-0.3	0.43	0.33	-0.41	-0.5	0.06	-0.22	-0.36	0.43	-0.72	-0.06	0.19	0.05	0.56	0.31	0.4	-0.07
Accounts Payable	0.63	0.89	0.49	0.8	0.54	0.54	0.28	-0.3		-0.02	-0.32	-0.15	0.52	0.47	-0.64	0.87	0.82	0.04	0.45	-0.23	-0.67	0.43	-0.81	-0.77	-0.47	0.74
Current Deferred Revenue	-0.3	-0.36	-0.14	-0.42	-0.05	-0.24	-0.31	-0.3	-0.02		-0.07	0.11	-0.23	-0.23	0.59	0.06	-0.1	0.02	0.03	-0.11	-0.56	-0.05	0.07	0.01	0.04	0.04
Short Term Investments	-0.06	-0.06	-0.2	-0.09	0.21	-0.07	0.34	0.43	-0.32	-0.07		0.05	-0.26	-0.23	0.33	-0.14	-0.26	0.21	-0.35	-0.28	-0.02	-0.27	0.46	0.31	0.32	-0.2
Common Stock	0.05	-0.1	0.01	-0.16	0.38	0.13	0.18	0.33	-0.15	0.11	0.05		-0.01	-0.06	0.42	0.07	-0.04	-0.14	-0.11	-0.18	-0.22	-0.15	0.27	0.21	0.18	-0.16
Intangible Assets	0.74	0.58	0.98	0.31	0.52	0.76	0.18	-0.41	0.52	-0.23	-0.26	-0.01		0.76	-0.46	0.53	0.86	-0.74	0.65	-0.27	-0.16	0.0	-0.78	-0.39	-0.58	0.02
Long Term Debt	0.78	0.53	0.8	0.39	0.54	0.88	0.56	-0.5	0.47	-0.23	-0.23	-0.06	0.76		-0.5	0.52	0.69	-0.54	0.93	-0.01	-0.23	0.19	-0.54	-0.22	-0.29	0.04
Treasury Stock	-0.62	-0.74	-0.39	-0.81	-0.27	-0.52	-0.36	0.06	-0.64	0.59	0.33	0.42	-0.46	-0.5		-0.46	-0.57	-0.02	-0.31	-0.28	-0.05	-0.41	0.56	0.42	0.32	-0.37
Property Plant Equipment	0.8	0.83	0.58	0.7	0.82	0.72	0.52	-0.22	0.87	0.06	-0.14	0.07	0.53	0.52	-0.46		0.88	-0.04	0.47	-0.38	-0.73	0.31	-0.64	-0.47	-0.38	0.47
Good Will	0.88	0.81	0.86	0.59	0.73	0.82	0.38	-0.36	0.82	-0.1	-0.26	-0.04	0.86	0.69	-0.57	0.88		-0.41	0.6	-0.34	-0.5	0.23	-0.83	-0.5	-0.57	0.29
Net Tangible Assets	-0.34	0.01	-0.73	0.27	-0.2	-0.45	0.06	0.43	0.04	0.02	0.21	-0.14	-0.74	-0.54	-0.02	-0.04	-0.41		-0.53	0.16	-0.1	0.39	0.33	-0.08	0.23	0.41
Long Term Debt Total	0.58	0.38	0.71	0.24	0.36	0.7	0.34	-0.72	0.45	0.03	-0.35	-0.11	0.65	0.93	-0.31	0.47	0.6	-0.53		-0.01	-0.32	0.19	-0.56	-0.27	-0.28	0.14
Long Term Investments	-0.23	-0.24	-0.27	0.02	-0.42	-0.19	-0.14	-0.06	-0.23	-0.11	-0.28	-0.18	-0.27	-0.01	-0.28	-0.38	-0.34	0.16	-0.01		0.44	0.07	0.19	0.12	0.13	-0.08
Accumulated Depreciation	-0.35	-0.47	-0.22	-0.36	-0.6	-0.36	-0.32	0.19	-0.67	-0.56	-0.02	-0.22	-0.16	-0.23	-0.05	-0.73	-0.5	-0.1	-0.32	0.44		-0.28	0.35	0.44	0.13	-0.55
Short Long Term Debt	0.26	0.35	-0.01	0.45	0.09	0.21	0.27	0.05	0.43	-0.05	-0.27	-0.15	0.0	0.19	-0.41	0.31	0.23	0.39	0.19	0.07	-0.28		-0.24	-0.24	-0.17	0.38
Cash And Equivalents	-0.54	-0.7	-0.73	-0.51	-0.31	-0.48	0.06	0.56	-0.81	0.07	0.46	0.27	-0.78	-0.54	0.56	-0.64	-0.83	0.33	-0.56	0.19	0.35	-0.24		0.81	0.81	-0.48
Net Invested Capital	-0.18	-0.65	-0.33	-0.59	-0.13	-0.13	0.17	0.31	-0.77	0.01	0.31	0.21	-0.39	-0.22	0.42	-0.47	-0.5	-0.08	-0.27	0.12	0.44	-0.24	0.81		0.69	-0.8
Net Working Capital	-0.33	-0.39	-0.58	-0.24	-0.18	-0.29	0.18	0.4	-0.47	0.04	0.32	0.18	-0.58	-0.29	0.32	-0.38	-0.57	0.23	-0.28	0.13	0.13	-0.17	0.81	0.69		-0.17
Capital Stock	0.04	0.65	-0.03	0.7	0.09	-0.02	-0.03	-0.07	0.74	0.04	-0.2	-0.16	0.02	0.04	-0.37	0.47	0.29	0.41	0.14	-0.08	-0.55	0.38	-0.48	-0.8	-0.17

Click cells to compare fundamentals

About Abbott Laboratories Financial Statements

Abbott Laboratories shareholders use historical fundamental indicators, such as Total Assets, to determine how well the company is positioned to perform in the future. Although Abbott Laboratories investors may analyze each financial statement separately, they are all interrelated. The changes in Abbott Laboratories' assets and liabilities, for example, are also reflected in the revenues and expenses on on Abbott Laboratories' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Total Assets	73.2 B	36.9 B
Intangibles To Total Assets	0.44	0.29

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Abbott Stock Analysis

When running Abbott Laboratories' price analysis, check to measure Abbott Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abbott Laboratories is operating at the current time. Most of Abbott Laboratories' value examination focuses on studying past and present price action to predict the probability of Abbott Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abbott Laboratories' price. Additionally, you may evaluate how the addition of Abbott Laboratories to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC